Tags: Drug.
Pirfenidone (INN BAN) is a drug developed by InterMune Inc. for the treatment of idiopathic pulmonary fibrosis (IPF). In 2011 it was approved for use in Europe for IPF under the trade name Esbriet. The proposed trade name in the US is also Esbriet.In Japan it is marketed as Pirespa by Shionogi & Co. In October 2010 the Indian Company Cipla launched it as Pirfenex. In September 2011 the Chinese State Food and Drug Administration provided GNI Group Ltd with approval of pirfenidone in China.
